Skip Ribbon Commands
Skip to main content
Navigate Up
EnglishFrancais
Current Year Centre for Addiction
and Mental Health

Antipsychotics common for adults with intellectual and developmental disabilities

Six-year Canadian study shows prescriptions often occur in adults with no psychiatric diagnosis
 
TORONTO, August 23, 2017 – Antipsychotic medication is frequently being prescribed to individuals with intellectual and developmental disabilities (IDD), often without a psychiatric diagnosis, a new study conducted by the Institute for Clinical Evaluative Sciences (ICES) and the Centre for Addiction and Mental Health (CAMH) has found. IDD includes diagnoses such as Down syndrome, fetal alcohol syndrome and autism.
 
The study, published today in The Canadian Journal of Psychiatry, has made significant strides in filling the gap in research about prescribing practices of antipsychotic medication to adults with IDD. The six-year population-based study examined the health care data of 51,881 adults with IDD who were less than 65 years of age. Similar research has been conducted in other jurisdictions; however, this study is the first population-based study to investigate the use of antipsychotic medication in adults with IDD in Canada.
 
“The results of our study make us question how often antipsychotics are being used as tool to manage behavioural issues. We need to understand more about why these medications are prescribed to those without psychiatric disorders, what else has been tried prior to medication, and how well these medications are being monitored,” says lead author Dr. Yona Lunsky​, adjunct scientist at ICES, a clinician-scientist at CAMH and director of the Health Care Access Research and Developmental Disabilities (H-CARDD) research program.
 
Antipsychotics can be prescribed to adults with IDD as a method of managing behavioural challenges, sometimes without a comprehensive assessment of the underlying contributors to such behaviours, despite the evidence supporting such use being inconclusive.  According to guidelines, antipsychotics should not be used as a first line treatment for behaviour challenges.
 
“This study shows that antipsychotic use in adults with IDD is common. We need to pay more attention to how antipsychotics are prescribed and monitored to ensure appropriate prescribing for this vulnerable population,” says Tara Gomes, co-author on the study, a scientist at ICES and a principal investigator of Ontario Drug Policy Research Network (ODPRN).
 
The researchers add that antipsychotic prescribing is particularly problematic for this population due to the potential for adverse effects such as the increased risk for metabolic complications. In this study, one in six adults had diabetes and one in five had hypertension. Furthermore, adults with IDD may have difficulties in providing informed medical consent and reporting unfavourable side effects should they arise.
 
The six-year study found:
  • 39 per cent of  Ontario adults with IDD  were dispensed antipsychotic medication (20,316 individuals)
  • 29 per cent of the antipsychotic users did not have a documented psychiatric diagnosis
 
This study also analyzed a sub-cohort of adults with IDD living in Ontario group homes and found:
  • 56 per cent (4,073) of  individuals residing in group homes were prescribed an antipsychotic
  • Of the antipsychotic users in a group home setting, 43 per cent did not have a documented psychiatric diagnosis
 
These findings are in line with a major UK study also demonstrating high antipsychotics use, sometimes in the absence of a psychiatric diagnosis. The STOMP movement in the UK is a shared commitment by the Colleges of Psychiatrists, Pharmacists, General Practitioners, Nurses, Psychologists and the National Health Service to curb the over-prescription of psychotropic medications to persons with IDD.
 
“Ideally this research, by providing a glimpse into antipsychotic prescribing practices among adults with IDD in Ontario will trigger a national conversation about medication policies, practices and training here,” adds Lunsky.
 
“Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities,” was published today in the Canadian Journal of Psychiatry.
 
-30-
 
 The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in its field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.

For more information, please follow @CAMHnews and @CAMHResearch on Twitter.

For further information or to arrange an interview please contact:
Sean O'Malley
Media Relations, CAMH
416 535-8501 ext. 36663
 
​​
 
Dr. Yona Lunsky
 
CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario